- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Payers Restrict Coverage for Proton Radiation Therapy
Weighing the cost-benefit ratio of proton radiation therapy, private and public payers are placing coverage limitations on the use of this treatment.
As proton cancer treatment centers expand, payers and providers may have to collaborate to expand the evidence base, to avoid the highly-expensive technology crowding out other investments.
The Midwest’s first proton beam cancer therapy center is closing its doors amid ongoing efficacy questions and financial struggles. At the advice of an outside review committee, Indiana University Health is closing its proton therapy center early next year, once the current roster of patients have completed treatment.
IU Health’s center was the nation’s third proton treatment facility and the Midwest’s first when it opened in 2004. It offered cancer patients the potential of more selective radiation treatment with fewer side effects, but ten years later, its clinical benefits remain unclear, its technology is slightly outdated and its finances seem unsustainable.
Read the complete article: http://bit.ly/1sYeOOB
Source: Healthcare Payer News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
